Citigroup Maintains Buy Rating on Evolent Health, Lowers PT to $4

Thursday, Feb 26, 2026 3:37 pm ET1min read
C--
EVH--

Citigroup Maintains Buy Rating on Evolent Health, Lowers PT to $4

Stay ahead of the market.

Get curated U.S. market news, insights and key dates delivered to your inbox.

Comments



Add a public comment...
No comments

No comments yet